https://www.selleckchem.com/pr....oducts/miransertib.h
TrkB/BDNF signaling may be a new therapeutic target for PDAC. Therapies targeting TrkB/BDNF signaling may be a conclusive cancer therapy for refractory solid cancer. Metastases of meningiomas are infrequent and the site of extracranial metastasis such as the bone is extremely rare. A 75-year-old male had a history of five sessions of surgery and gamma-knife treatment for brain meningioma over a period of 29 years. He visited our hospital because he noticed a swelling in his anterior chest 2 years and 6 months after the final treatme
Aimer
Commentaire
Partagez
